- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03531736
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
Allogeneic Hematopoietic Stem Cell Transplantation of α/β T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation described in the study is considered 'low intensity.' Although the chemotherapy agents used in this study and for transplant are FDA approved, the chemotherapy treatment and conditioning regimens or combinations listed in this consent are not yet FDA approved.
The CliniMACS device is FDA approved for one type of T cell depletion (positive selection of the stem cells) but not approved yet for other type of T cell depletion, which is being studied on this protocol. This pilot study, along with other studies will serve as the basis for FDA approval, if outcomes are favorable.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Roni Tamari, MD
- Phone Number: 212-639-5987
- Email: ABMTTrials@mskcc.org
Study Contact Backup
- Name: Miguel-Angel Perales, MD
- Phone Number: 212-639-8682
- Email: ABMTTrials@mskcc.org
Study Locations
-
-
New Jersey
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with one of the high risk myeloid diseases as outlined below. Patients must have ≤ 5% blasts on the last BM evaluation prior to starting the conditioning regimen. Diseases included on this protocol include:
Acute Myeloid Leukemia (AML) in CR1 with intermediate or high risk features as defined below:
°Cytogenetic abnormalities which are not considered "good risk" cytogenetic features (i.e t(8:21), t(15:17), inv 16 without c-kit mutations.
And/or
- Therapy related AML with history of antineoplastic therapy (radiation and/or chemotherapy) And/or
- Normal karyotype with mutations of FLT3, RUNX1, TP53 mutation, ASXL1 or any others that are considered to be high risk
- AML in ≥ 2nd remission
Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with:
°International prognostic scoring system risk score INT-2 or high risk at the time of transplant evaluation.
And/or
- Any risk category if life-threatening cytopenia exists And/or
- Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.
- Chronic myelomonocytic leukemia (CMML)
Chronic myeloid leukemia (CML) with the following features:
°Patients who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitors.
And/or
°CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g T351l mutation)
- Patients with severe aplastic anemia
- Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria.
Non-Hodgkin lymphoma meeting both of the following criteria:
- Responding to therapy prior to enrollment.
- Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant.
Multiple Myeloma with disease in the following categories:
- Patients with relapsed multiple myeloma following autologous stem cell transplantation who have achieved at least partial response following additional chemotherapy
- Patients with high risk cytogenetics at diagnosis must have achieved at least a partial response following autologous stem cell transplantation. Patients must have complex karyotype, del17p, t4;14, and/or t14;16 by FISH and/or del13 by karyotyping.
- Each patient must be willing to participate as a research participant and must sign an informed consent form.
Organ Function and Performance Status Criteria:
- Patients be ≥ 18 years old.
- Patients must have a Karnofsky (adult) or Performance Status ≥ 70%.
Patients must have adequate organ function measured by:
- Cardiac: asymptomatic or if symptomatic, then LVEF at rest must be ≥ 40% and must improve with exercise.
- Hepatic: < 5x ULN ALT and < 2x ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.
- Renal: CrCl >30ml/min (measured or calculated/estimated).
- Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted (corrected for hemoglobin)
Exclusion Criteria:
- Prior allogenic hematopoietic stem cell transplantation
- Prior radiation therapy with 400cGY or more of TBI
- BM with increased fibrosis (Reticulin stain > 1/3)
- Active and uncontrolled infection at time of transplantation
- HIV infection
- Seropositivity for HTLV-1
- Inadequate performance status/ organ function
- Pregnancy or breast feeding
- Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.
Donor Inclusion and Exclusion Criteria:
- Must be a 10/10 HLA genotypically match related or unrelated donor at all A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis
- Able to provide informed consent for the donation process per institutional standards
- Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with Myeloid Malignancies & Aplastic Anemia
Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4).
One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia.
The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg.
Patients will receive post-transplant G-CSF starting on day +7.
Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician.
Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
|
ATG (2 mg/kg/d IV on days-8 through -7)
Other Names:
fludarabine (30 mg/m2/d on days -5 through -2)
TBI 200 cGy (days -2 and -1) given post stem cell infusion
Other Names:
cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia
Allogeneic Hematopoietic Stem Cell Transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of donor Neutrophil Engraftment
Time Frame: 30 days post-transplant
|
Neutrophil engraftment (recovery of ANC) defined by an ANC ≥ 500/mm^3 for 3 consecutive days
|
30 days post-transplant
|
Collaborators and Investigators
Investigators
- Principal Investigator: Roni Tamari, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Anemia
- Bone Marrow Failure Disorders
- Hematologic Neoplasms
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Cyclophosphamide
- Rituximab
- Fludarabine
- Thymoglobulin
- Antilymphocyte Serum
Other Study ID Numbers
- 17-639
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloid Diseases
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingMyeloid Malignancy | Relapsed/Refractory Acute Myeloid LeukaemiaChina
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Myeloid Neoplasm | Myeloid Sarcoma | Leukemia CutisUnited States, Canada, Australia, New Zealand, Puerto Rico
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedAcute Myeloid LeukaemiaFrance, United States, Australia
-
Yale UniversityPfizerTerminatedACUTE MYELOID LEUKEMIAUnited States
-
AstraZenecaCompletedAcute Myeloid LeukaemiaUnited Kingdom
-
University of WashingtonTerminatedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloid NeoplasmUnited States
Clinical Trials on Antithymocyte globulin (Rabbit)
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedNew-onset Type 1 Diabetes MellitusUnited States
-
University of CalgaryAlberta Health services; University of AlbertaTerminated
-
The Methodist Hospital Research InstituteUnknownAcute (Cellular) Renal Allograft RejectionUnited States
-
Tehran University of Medical SciencesUnknownMucopolysaccharidosisIran, Islamic Republic of
-
European Society for Blood and Marrow TransplantationGenzyme, a Sanofi CompanyCompletedAplastic AnemiaSwitzerland, United Kingdom, Germany, Italy, France, Saudi Arabia
-
Medical University of South CarolinaGenzyme, a Sanofi CompanyCompletedEnd Stage Renal DiseaseUnited States
-
Ohio State University Comprehensive Cancer CenterCelgene CorporationRecruitingCutaneous T-cell Lymphoma | Peripheral T-Cell Lymphoma | T-Prolymphocytic Leukemia | T-Large Granulocytic Leukemia | T-Lymphoblastic Leukemia/LymphomaUnited States
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital Research... and other collaboratorsCompletedSafety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation (STAT)End-Stage Renal Disease | Kidney FailureUnited States
-
Chinese PLA General HospitalRecruitingHaploidentical Hematopoietic Stem Cell TransplantationChina
-
University of CincinnatiGenzyme, a Sanofi CompanyCompletedRenal Transplant Rejection | Transplants and ImplantsUnited States